Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

X
Trial Profile

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELND 005 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms Harmony AD; Harmony-AD; HarmonyAD
  • Sponsors Transition Therapeutics
  • Most Recent Events

    • 10 Nov 2015 According to a Transition Therapeutics media release, data from this trial was presented at the Clinical Trials in Alzheimer's Disease (CTAD) meeting.
    • 28 Oct 2015 Data from this trial will be presented at the Clinical Trials in Alzheimer's Disease (CTAD) 2015, according to a Transition Therapeutics media release.
    • 15 Oct 2015 Data of this trial will also be presented at the Clinical Trials in Alzheimer's Disease meeting in Barcelona, as per Transition Therapeutics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top